Literature DB >> 9272733

The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.

M C Haaz1, L P Rivory, C Riché, J Robert.   

Abstract

Irinotecan (CPT-11) is a new camptothecine derivative presently in development for the treatment of several advanced malignancies. It is converted in vivo to a highly potent metabolite, SN-38, by carboxylesterases. All camptothecine derivatives undergo lactonolysis in a pH-dependent reversible manner, generating inactive carboxylate forms. We have investigated in vitro the kinetics of transformation of CPT-11 to SN-38 by human liver microsomes originating from several donors. Microsomes from seven livers were studied individually or as a pooled preparation. CPT-11, either in its lactone or its carboxylate form, was added at a range of concentrations. The SN-38 formed was measured by HPLC with fluorometric detection. In the deacylation-limited carboxylesterase reaction, the linear steady-state kinetics between 10 and 60 min were determined. At all concentrations of CPT-11, the steady-state velocity of SN-38 formation as well as the intercept concentrations of SN-38 were about 2-fold higher when the substrate was under the lactone form than under the carboxylate form. We estimated the values (+/-SD) of K'm and Vmax to be 23.3 +/- 5.3 microM and 1.43 +/- 0.15 pmol/min/mg for the lactone and 48.9 +/- 5.5 microM and 1.09 +/- 0.06 pmol/min/mg for the carboxylate form of CPT-11, respectively. We conclude that the greater rate of conversion of CPT-11 lactone may contribute to the plasma predominance of SN-38 lactone observed in vivo. The inter-individual variation of SN-38 formation was relatively high (ratio of 4 between extreme values) but no large age- or gender-related differences were seen. The effect of twelve drugs of different therapeutic classes (antibiotics, antiemetics, antineoplastics, antidiarrhoeics, analgesics), which could be administered in association with irinotecan in the clinical setting, was evaluated in this system (drug concentration: 100 microM; CPT-11 lactone concentration: 10 microM). Loperamide and ciprofloxacine where the only drugs exerting a weak inhibition of CPT-11 conversion to SN-38.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272733     DOI: 10.1007/pl00005049

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  7 in total

1.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

2.  The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.

Authors:  Peter Tobin; Stephen Clarke; J Paul Seale; Soon Lee; Michael Solomon; Sally Aulds; Michael Crawford; James Gallagher; Tony Eyers; Laurent Rivory
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 3.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

4.  Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.

Authors:  Mikael Boberg; Marc Vrana; Aanchal Mehrotra; Robin E Pearce; Andrea Gaedigk; Deepak Kumar Bhatt; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2016-11-28       Impact factor: 3.922

Review 5.  Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

Authors:  Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

6.  CPT11 with P-glycoprotein/CYP 3A4 dual-function inhibitor by self-nanoemulsifying nanoemulsion combined with gastroretentive technology to enhance the oral bioavailability and therapeutic efficacy against pancreatic adenocarcinomas.

Authors:  Ling-Chun Chen; Wei-Jie Cheng; Shyr-Yi Lin; Ming-Tse Hung; Ming-Thau Sheu; Hong-Liang Lin; Chien-Ming Hsieh
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

7.  A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

Authors:  N E Schoemaker; I E L M Kuppens; V Moiseyenko; B Glimelius; M Kjaer; H Starkhammer; D J Richel; R Smaaland; K Bertelsen; J P Poulsen; E Voznyi; J Norum; D Fennelly; K M Tveit; A Garin; G Gruia; A Mourier; D Sibaud; P Lefebvre; J H Beijnen; J H M Schellens; W W ten Bokkel Huinink
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.